Ipamorelin FAQ: Risks, Side Effects, Half-Life, and the Evidence
What are the risks of ipamorelin?
The main risk is the unknown: no long-term human safety study exists, and the one efficacy RCT (n=114, ≤7-day IV) showed no specific safety signal but also missed its endpoint [3]. Documented concerns are class-level and mechanistic — GH-axis effects on glucose and fluid, a theoretical IGF-1/cancer concern [4], and a cardiotoxicity signal from a 28-day rat study of a related receptor agonist [6].
What are the downsides of ipamorelin?
The biggest downside is that it has not been shown to work for anything in humans — its only Phase 2 trial missed its primary endpoint (25.3 h vs 32.6 h, p=0.15) [3]. Other downsides: no approved status, no long-term safety data [3], unverified purity of research-grade material, and a WADA S2 ban in sport. Reported nuisance effects include flushing and mild puffiness, anecdotally.
Does ipamorelin cause cancer?
No ipamorelin study has shown it causes cancer, and none has tested the question in humans. The concern is theoretical and mechanistic: GH stimulates IGF-1, a mitogen that promotes cell proliferation [1][4], so chronically raising GH could in theory accelerate growth in a pre-existing tumor. There is no observed oncologic event in any ipamorelin study to confirm or refute this — the long-term human data simply do not exist [3].
What are the side effects of CJC-1295 and ipamorelin?
No controlled human trial has characterized side effects of the combination [3]. Commonly reported (anecdotal) effects include facial flushing, mild water retention, tingling in the extremities, increased hunger, lightheadedness, and injection-site irritation. Mechanistic cautions apply to the ipamorelin component — glucose effects [13], appetite stimulation [15], and a class cardiotoxicity signal [6] — none resolved in humans.
Does ipamorelin affect cortisol or prolactin?
Minimally — that is its defining feature. In its founding characterization, ipamorelin released GH potently (swine ED50 2.3 nmol/kg) yet did not raise ACTH or cortisol above the GHRH baseline even at more than 200× its GH ED50 [1]. This cortisol- and prolactin-sparing selectivity is what distinguished it from earlier growth-hormone-releasing peptides like GHRP-6 and GHRP-2 [1].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary to release a pulse of growth hormone, without meaningfully raising cortisol or prolactin [1]. Developed by Novo Nordisk in the 1990s, it was the first highly selective growth hormone secretagogue and has never been approved as a drug [3].
What does ipamorelin do for you?
In studies, ipamorelin releases a discrete pulse of growth hormone via the ghrelin receptor [1] and, in rodents, increased longitudinal bone growth and body weight [4][7]. In people, the one efficacy trial (for bowel-function recovery) did not work [3]. Community users anecdotally report better sleep and recovery, but these are unverified reports, not demonstrated human outcomes.
What is ipamorelin peptide?
"Ipamorelin peptide" is the same compound: a five-amino-acid (pentapeptide) growth hormone secretagogue, formula C₃₈H₄₉N₉O₅, ~711.9 Da, CAS 170851-70-4 [1]. It is wholly synthetic, derived from GHRP-1, and acts as a selective ghrelin-receptor (GHS-R1a) agonist [1]. It is not an endogenous human peptide and not an approved medicine [3].
Does ipamorelin reduce belly fat?
No human trial has tested ipamorelin for belly fat. The closest in-vivo data is a 2024 ferret study where ipamorelin (1–3 mg/kg IP) inhibited cisplatin-induced weight loss by about 24% but had no anti-emetic effect [5] — a weight-preservation effect, not fat loss. Community users occasionally report a gradual leaner look over weeks, but that is anecdotal and confounded by diet and training.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product, so there is nothing to "discontinue" in that sense — its clinical development stopped because its only Phase 2 trial (postoperative ileus) missed its primary endpoint [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 2024 PCAC meeting, tightening compounding-pharmacy access.
What does CJC-1295 and ipamorelin do?
They release growth hormone through two different receptors — CJC-1295 via the GHRH receptor, ipamorelin via the ghrelin receptor — and can act synergistically [9]. A 2026 review found the combination improved muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while stressing evidence is limited to animal studies [18]. No human outcome trial of the combination exists [3].
Does ipamorelin increase IGF-1?
Not consistently in short studies. Ipamorelin releases GH, which can raise hepatic IGF-1 over time, but in a 15-day rat bone-growth study total IGF-1 did not change despite dose-dependent bone growth — pointing to a partly local, GH-pulse-driven effect [4]. In a diabetic-mouse model, the IGF-1 response was actually absent alongside hepatic GH-receptor resistance [8]. So IGF-1 elevation is context-dependent, not guaranteed.
How does CJC-1295 ipamorelin work?
CJC-1295 (a GHRH analog) raises GH through the GHRH receptor's cAMP pathway, while ipamorelin activates the ghrelin receptor (GHS-R1a) through the calcium pathway [1]. Because they hit different doors, combining them can produce GH release greater than either alone — true synergism shown for a GHRP plus GHRH in humans (P=0.001) [9]. The synergy is the mechanistic rationale for the pairing.
How much CJC-1295 ipamorelin should I take?
No published human trial supports a dose for the combination, and this site does not provide one. Its evidence is single-agent pharmacology plus animal work; a 2026 review noting a muscle effect in mice explicitly said evidence is limited to animal studies [18]. Community subcutaneous regimens have no peer-reviewed human dosing basis and are anecdotal, not recommended [3].
Does CJC-1295 ipamorelin work?
For raising GH acutely, yes — GHRP + GHRH combinations produce synergistic GH release and prolonged GHRP-6 infusion more than doubled integrated GH in men [10]. For clinical outcomes like fat loss or muscle in humans, it has not been demonstrated in controlled trials [3]. The 2026 evidence remains animal-only for the combination's functional effect [18].
How to reconstitute CJC-1295 ipamorelin 5mg?
As research handling, not a use instruction: ipamorelin is supplied as a lyophilized (freeze-dried) powder and, in the research-supply literature, reconstituted with bacteriostatic water, then kept refrigerated because peptides degrade with heat and freeze-thaw. The "5mg" is a supplier vial-labeling convention, not a validated dose. No human dosing is provided, and the human PK basis comes from IV studies [2].
How long does ipamorelin stay in your system?
About 2 hours terminal half-life by vein in healthy volunteers, with the GH pulse peaking around 40 minutes after dosing [2]. After roughly four to five half-lives (≈8–10 hours) it is effectively cleared. Note that anti-doping detection windows can outlast the plasma half-life — a short half-life does not mean a short detection window. Subcutaneous human kinetics are uncharacterized [3].
Does ipamorelin make you hungry?
It can, by mechanism — ipamorelin works on the ghrelin ("hunger hormone") receptor, and ghrelin-receptor agonists activate the brain's appetite centers and induce feeding as a class [15]. Some community users report an uptick in appetite after injecting (anecdotal), generally described as milder than with GHRP-6. An ipamorelin-derived oral analog also produced body-weight gain over 14 days in rats [7].
Will I gain weight on ipamorelin?
Possibly via two routes the data show: increased appetite (ghrelin-receptor mechanism) [15] and a GH-independent stimulation of adiposity and leptin seen in mice after two weeks of dosing [14]. In rats, an ipamorelin-derived analog produced significant body-weight gain over 14 days [7]. No human body-weight trial of ipamorelin exists [3], so individual outcomes are uncharacterized and confounded by diet.
Does ipamorelin increase appetite?
Yes, by its mechanism. As a ghrelin-receptor (GHS-R1a) agonist, ipamorelin engages the same receptor the hunger hormone ghrelin uses, and central administration of ghrelin and GH secretagogues activates hypothalamic appetite centers and induces feeding [15]. Community accounts describe increased hunger after injecting as an occasional, usually mild effect (anecdotal). The class signal is well established even though ipamorelin-specific human appetite data are absent.
What does ipamorelin peptide do?
It selectively triggers a pulse of growth hormone by activating the ghrelin receptor (GHS-R1a) on the pituitary, without meaningfully raising cortisol or prolactin [1]. In animals it increased bone growth and body weight [4][7]; in humans its one efficacy trial failed [3]. It is a research peptide, not an approved drug, and produces a single GH pulse peaking ~40 minutes post-dose [2].
How long does it take for ipamorelin to work?
The hormonal effect is fast: the growth-hormone pulse peaks about 40 minutes (0.67 h) after an IV dose [2]. Any felt effects people describe — like sleep changes — are reported anecdotally to appear over one to two weeks of a routine, but these are unverified community reports, not measured outcomes. The peptide itself clears within hours, with a ~2-hour terminal half-life [2].